Načítá se...
Safety and tolerability of oral lisdexamfetamine in adults with methamphetamine dependence: a phase-2 dose-escalation study
OBJECTIVES: To examine the safety of an agonist-type treatment, lisdexamfetamine (LDX), at 250 mg/day among adults with methamphetamine (MA) dependence. DESIGN: A dose-escalating, phase-2, open-label, single-group study of oral LDX at two Australian drug treatment services. SETTING: The study was co...
Uloženo v:
| Vydáno v: | BMJ Open |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BMJ Publishing Group
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8137170/ https://ncbi.nlm.nih.gov/pubmed/34006547 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2020-044696 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|